Yuping Gong

机构：Sichuan University, West China Hospital of Sichuan University · ORCID：0000-0002-2437-9348

发表论文 150 篇 · 总被引 2101 次 · h-index 24

代表论文

• Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study (2024 · The Lancet Haematology · 被引 29)
• Myelomonocytic and monocytic acute myeloid leukemia demonstrate comparable poor outcomes with venetoclax-based treatment: a monocentric real-world study (2024 · Annals of Hematology · 被引 17)
• Prognosis and risk factors for ASXL1 mutations in patients with newly diagnosed acute myeloid leukemia and myelodysplastic syndrome (2023 · Cancer Medicine · 被引 14)
• The clinical features and prognostic implications of PTPN11 mutation in adult patients with acute myeloid leukemia in China (2023 · Cancer Medicine · 被引 5)
• METTL3 , an Independent Adverse Prognostic Factor for AML , Promotes the Development of AML by Modulating the PGC ‐1α– MAPK Pathway and PGC ‐1α–Antioxidant System Axis (2025 · Cancer Medicine · 被引 3)
• Zuberitamab, an innovative anti-CD20 monoclonal antibody, for patients with primary immune thrombocytopenia in China: a randomized, double-blind, placebo-controlled, phase 2 study (2024 · The Lancet Regional Health - Western Pacific · 被引 3)